Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and six have given a buy rati...
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and six have given a buy rati...
(RTTNews) - Corbus Pharmaceuticals Holdings, Inc. (CRBP), a company focused on oncology and obesity, said on Monday that it has appointed Leonardo Viana Nicacio as Chief Medical Officer...
Corbus Pharmaceuticals (NASDAQ:CRBP) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-corbus-pharmaceuticals-holdings-inc-stock...
Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten research firms that are presently covering the...
Aberdeen Group plc lifted its position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 602.2% during the 4th quarter, according to the company in its most recent disclosure...